Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + carboplatin + etoposide + radiotherapy
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, External
01
Overview
Adebrelimab (SHR-1316) is a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1). It is designed to block the interaction between PD-L1 and its receptor PD-1, thereby enhancing T-cell mediated immune responses against tumor cells. Adebrelimab has been investigated in combination with chemotherapy agents such as carboplatin and etoposide, along with sequential chest radiotherapy, primarily for the treatment of extensive-stage small cell lung cancer (ES-SCLC). Clinical studies have shown that this combination demonstrates promising efficacy and an acceptable safety profile as a first-line therapy for ES-SCLC. The drug is developed by Jiangsu Hengrui Medicine.
- Brand names
- Ariely
- Other names
- adebrelimabSHR-1316SHR1316SHR 1316
02
Targets
TOP2A (DNA topoisomerase II)CD274 (Programmed cell death protein 1 ligand 1)DNA
Beyond the preview
Go deeper on adebrelimab + carboplatin + etoposide + radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + carboplatin + etoposide + radiotherapy.